Tag: Phase 3 study
October 11, 2019
RedHill Biopharma Releases Positive Results from MAP US Phase 3 Study
The company announced positive results from its MAP US Phase 3 Study and MAP US2 Open-Label Extension Study August 22, 2019
Retrophin Announces Topline Results from Phase 3 FORT Study
Retrophin (NASDAQ:RTRX) has announced that the Phase 3 FORT study evaluating the safety and efficacy of fosmetpantotenate compared to a... May 9, 2018
Foamix Reports First Quarter 2018 Financial Results and Provides Corporate Update
Foamix Pharmaceuticals (NASDAQ:FOMX) a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs...
April 29, 2018
5 Top Weekly NASDAQ Biotech Stocks: Eleven Biotherapeutics Up 45 Percent
Eleven Biotherapeutics, EyePoint Pharmaceuticals, Avid Bioservices, Cerecor and Celldex were last week's top gainers on the NASDAQ.
April 26, 2018
Kalytera Issues CEO Letter to Shareholders
Kalytera Therapeutics, Inc. (TSXV:KALY, OTCQB:KALTF) (the "Company" or "Kalytera") today issued the following letter to shareholders from the Company’s President...
April 24, 2018
Pharmaceutical Update: Q1 in Review
What happened in Q1 2018 for the pharma industry? Here's a look back at some of the quarter's biggest news... April 19, 2018